The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / HSCT for Severe Autoimmune Diseases

HSCT for Severe Autoimmune Diseases

August 14, 2017 • By Ruth Jessen Hickman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Despite the innovations of new biologics and disease-modifying anti-rheumatic drugs, a large unmet need remains for patients with rheumatic autoimmune disease. Treatment remains limited for many conditions, including for conditions with a dim prognosis, such as systemic sclerosis.1 One promising treatment avenue is hematopoietic stem-cell transplantation (HSCT). Here, we provide background on HSCT for severe rheumatic autoimmune disease, examine the perspectives of three patients who sought out clinical trials and provide a research update on systemic sclerosis.

You Might Also Like
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • T Cells & Autoimmune Diseases
Explore This Issue
August 2017
Also By This Author
  • FDA’s Arthritis Advisory Committee Narrowly Endorses Avacopan Approval

HSCT History & Current Status

In 1996, a patient with connective tissue disease and severe pulmonary hypertension underwent autologous HSCT—the first patient with rheumatic autoimmune disease reported to receive the treatment.2 Since that time, clinical research teams have performed HSCT for a number of different rheumatic autoimmune conditions, including systemic sclerosis, lupus, rheumatoid arthritis, juvenile idiopathic arthritis and, less commonly, for other conditions, such as Sjögren’s syndrome, mixed connective tissue disease, Behçet’s disease, psoriatic arthritis, ankylosing spondylitis and vasculitides.3,4

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Worldwide, teams have performed over 3,000 HSCT procedures for rheumatic and nonrheumatic autoimmune disease. These have been mostly autologous HSCT, as documented through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation.3

Researchers adopted the technique of HSCT from the fields of hematology and oncology.4 HSCT aims to reset an auto­reactive immune system. Current immunosuppressive and biological treatments for autoimmune rheumatological disease can successfully suppress immune response, but they are unable to target autoreactive immunologic memory. Moreover, they must be taken continuously in order to maintain immunosuppression. In contrast, HSCT therapies can potentially provide sustained, total remission of autoimmune syndromes without the need for ongoing therapy.

Dr. Georges Georges

Dr. Georges Georges

HSCT profoundly depletes the autoreactive immunologic memory (T cells and B cells) via high-dose chemotherapy. Conditioning regimens vary. In general though, stem cells are mobilized into the bloodstream by such treatments as granulocyte colony-stimulating factor and later collected. Several weeks later, patients undergo some version of immunoablative therapy, receiving such agents as anti-thymocyte globulin and cyclophosphamide. During this time, the autoreactive immunological memory is profoundly depleted. This is followed by autologous stem cell transplant, which reconstitutes a new immune system and reestablishes immune tolerance.3

After transplant, T cells appear to be largely derived from the stem-cell graft, and T regulatory cells display a renewed repertoire of T cell receptors.3,5 Autoantibodies are also substantively reduced after HSCT treatment.5

Kathy Peel had HSCT for her lupus in July 2016.

Kathy Peel had HSCT for her lupus in July 2016.

Pages: 1 2 3 4 5 6 7 8 | Single Page

Filed Under: Conditions Tagged With: Autoimmune, Biologics, Clinical, disease-modifying anti-rheumatic drugs, hematopoietic stem-cell transplantation, Juvenile idiopathic arthritis, Lupus, outcome, patient care, Research, Rheumatic Disease, Rheumatoid arthritis, rheumatology, Systemic sclerosis, TreatmentIssue: August 2017

You Might Also Like:
  • Stem Cell Transplantation Shown to Improve Outcomes in Systemic Sclerosis
  • The ACR’s State-of-the-Art Clinical Symposium: Stem Cell Therapy in Autoimmune Disease Evolution, Insights
  • T Cells & Autoimmune Diseases
  • Cellular Therapy of Autoimmune Disease

About Ruth Jessen Hickman, MD

Ruth Jessen Hickman, MD, was born and raised in eastern Kentucky, where she first cultivated her love of literature, writing and personal narratives. She attended Kenyon college, where she received a Bachelor of Arts in philosophy, summa cum laude. She worked with individuals with psychiatric conditions and later in a neuroscience lab at the University of Illinois, Chicago, before graduating from Indiana University Medical School in 2011. Instead of pursuing clinical medicine, Ruth opted to build on her strength of clearly explaining medical topics though a career as a freelance medical writer, writing both for lay people and for health professionals. She writes across the biomedical sciences, but holds strong interests in rheumatology, neurology, autoimmune diseases, genetics, and the intersection of broader social, cultural and emotional contexts with biomedical topics. Ruth now lives in Bloomington, Ind., with her husband, son and cat. She can be contacted via her website at ruthjessenhickman.com.

View more by this author»

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.